Speakers
Manzoor Hussain
Dhaka Shishu Children Hospital, BangladeshTitle: Impact of Screening of Critical Congenital Heart Disease in Newborn in Bangladesh by Pulse Oximetry
Abstract:
Screening for congenital heart diseases (CHD) in newborn babies aid in early recognition, with the prospect of improved outcome. Currently there is no effective screening protocol for this condition. Pulse oximetry is highly specific for detection of critical CHD with moderate sensitivity that meets criteria for universal screening. To evaluate the use of pulse oximetry as a screening tool in early detection of critical CHD specially duct dependent critical CHD in asymptomatic newborn babies. A cross sectional study conducted in Dhaka Shishu (Children) Hospital from October 2014 to June 2015. Newborns attended outpatient department or admitted in different wards with having gestational age >35 weeks and age between 24-48 hours were included and pulse oximetry screening was done. Oxygen saturation measurement <90%, or oxygen saturation measurements <95% in both extremities on three consecutive measurements separated by one hour, or a >3% absolute difference in oxygen saturation between the right hand & foot on three consecutive measurements was considered as pulse oximetry screening positive. Routine neonatal examination was done and clinical evidence of CHD was noted. Echocardiogram was done to rule out CHD. Data were analyzed by using SPSS and sensitivity, specificity and predictive values were calculated.
Biography:
Manzoor Hussain currently working at Dhaka Shishu Children Hospital, Bangladesh. his research interest in pediatrics and pediactric cardiology
Mudasir Nabi Peerzada
Medicinal Chemistry Research laboratory, IndiaTitle: Design, Synthesis and Pharmacological Assessment of Novel Aryloxime-Morpholine Hybrids as Potential Microtubule Affinity-Regulating Kinase 4 Inhibitors and Anticancer Agents
Abstract:
Human African and American trypanosomiasis are the vector-borne parasitic diseases that have killed millions of people early, and many people are still suffering from these neglected diseases. The causative agents of these infections are parasitic protozoans of the genus Trypanosoma. Current treatment regimens against these endemic diseases have several limitations in terms of safety, efficacy, route of administration, and some of them have lost efficacy due to the emergence of resistance in their respective parasites. In this review, the most promising compounds identified by different strategies of drug development against these neglected diseases, including target-based approach, the phenotypic high-throughput screening, the drug repurposing approach, and combination therapy, are emphasized. The potent heterocyclic compounds currently undergoing pre-clinical or clinical studies have also been assessed to ascertain an effective class of organic compounds having significant therapeutic potential against these tropical diseases. The molecular hybridization of outlined motifs may result in more active compounds and circumvent the development of resistance by specific targets in the future.
Biography:
Mudasir Nabi Peerzada done his Phd in Medicinal Chemistry Research Laboratory, JMI, New Delhi. Hameldiscovered the CSA4 antitumor drug along with Professor G. R. Pettit in 1989 and he ispresently the senior investigator at National Cancer Institute, NIH, Maryland USA,where he is mentoring the group of scientists. Professor Supuran is the inventor of SLC0111 antitumor agent, discoverer of eta-carbonic anhydrases and having more than95000 citations. He is the most cited scientist in the field of cancer drug discoveryresearch in the world having more than 1700 research papers to his credit and forty yearsof research experience in this field.This research entitled as “Deciphering the key heterocyclic scaffolds in targetingmicrotubules, kinases and carbonic anhydrases for cancer drug development”is publishedinthe high impact medical journal “Pharmacology & Therapeutics”(5 year impact factor11.40). This journal is included in the Index Medicus.